Clinical trials: Dyslipidemias
Dyslipidemia
Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Food in Dyslipidemic Adults
The incidence of chronic degenerative diseases, especially cardiovascular disease (CVD), is high world over and especially in India. High blood cholesterol and triglyceride levels are known to be important risk factors for CVD.
- Trial name
- NCT00422266
- Testing
- Omega 3 fatty acids and plant sterol enriched drink, Omega 3 fatty acids and plant sterols
- Where
- India
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Centre for Chronic Disease Control, India
Obesity, Overweight
The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids
Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and…
- Conditions
- Obesity, Overweight, Dyslipidemia
- Trial name
- NCT00526682
- Testing
- Irvingia/cissus combo
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gateway Health Alliance
Dyslipidemia/Glucose Metabolism Disorder
Acceptability of a Fixed Combination of Fenofibrate and Metformin
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
- Trial name
- NCT00348725
- Testing
- fenofibrate and metformin fixed combination (drug)
- Where
- 25 sites in France
- Volunteers
- 69 people
- Sponsor
- Solvay Pharmaceuticals
Dyslipidemia/Glucose Metabolism Disorder
Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and…
- Trial name
- NCT00349128
- Testing
- fenofibrate and metformin combination (drug)
- Where
- 51 sites in Poland, Ukraine and 1 more
- Volunteers
- 382 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2, Dyslipidemia
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
- Trial name
- NCT00490178
- Testing
- Fenofibrate 80 mg and metformin 1000 mg (fixed combination)
- Where
- 3 sites in France
- Volunteers
- 29 people
- Sponsor
- Solvay Pharmaceuticals
Hypertension, Type 2 Diabetes
Lifestyle Intervention in Primary Health Care - the Björknäs Study
The purpose of this study is to determine whether a short group intervention programe aiming at lifestyle changes at a local health centre can improve risk factors for cardiovascular disease
- Conditions
- Hypertension, Type 2 Diabetes, Obesity, Dyslipidemia
- Trial name
- NCT00486941
- Testing
- Exercise and diet - based on DPS and DPP
- Where
- Sweden
- Volunteers
- 151 people
- Sponsor
- Umeå University
HIV Infections, Hepatitis B
ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency
The purpose of this study is to determine the safety and effects in HIV patients of supplementation (4-20 fl. oz. daily) with ProAlgaZyme, a novel fermentation product of a freshwater algae ecosystem, on markers of immune status…
- Conditions
- HIV Infections, Hepatitis B, Dyslipidemia
- Trial name
- NCT00493506
- Testing
- ProAlgaZyme
- Where
- Cameroon
- Volunteers
- 59 people
- Sponsor
- Health Enhancement Products, Inc.
Type 2 Diabetes
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes
Diabetes is associated with dyslipidaemia leading to generalized atherosclerosis, cardiovascular disease (CVD) and nephropathy. Osteoprotegerin (OPG), a glycoprotein involved in bone homeostasis, has been implicated in the…
- Trial name
- NCT00471549
- Testing
- Statin (simvastatin)
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
Dyslipidemia
Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia
The objective of this proposal is to study the applicability of the hs-CRP assay in the assessment of CV risk in daily clinical conditions where hyperlipidemic population with or without CHD are currently evaluated.
- Trial name
- NCT00169871
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Diabetes Mellitus, Type 2, Metabolic Syndrome
Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia
Berberine has showed effective in lowering blood sugar levels in db/db mice and anti-dyslipidemia in human. These findings have not been tested in a clinical trial.
- Trial name
- NCT00462046
- Testing
- Berberine
- Volunteers
- 120 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Obesity, Dyslipidemia
Effect of Abdominal Obesity on Lipoprotein Metabolism
Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease.
- Conditions
- Obesity, Dyslipidemia, Insulin Resistance
- Trial name
- NCT00438061
- Testing
- Weight loss by dietary restriction
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Western Australia
HIV Infections
Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial
Highly active antiretroviral therapy (HAART) in HIV-positive patients is associated with the development of dyslipidemia, a risk factor for cardiovascular events.
- Trial name
- NCT00429845
- Testing
- Nutritional
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Dyslipidemia
A Study in People With Abnormal Fat Levels in the Blood
The purposes of this study are to determine: The safety of the study medication and any side effects that might be associated with it; Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C)…
- Trial name
- NCT00116519
- Testing
- PPAR alpha
- Where
- 54 sites in United States
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Hypertension
Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Hypertension, Dyslipidemia, Diabetic Nephropathy
- Trial name
- NCT00419484
- Testing
- pioglitazone
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Dokkyo Medical University
Dyslipidemia, Coronary Heart Disease
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Atherosclerosis, Stroke
- Trial name
- NCT00079638
- Testing
- Niacin, Atorvastatin, Simvastatin
- Volunteers
- 300 people
- Sponsor
- Kos Pharmaceuticals
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Hypercholesterolemia
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
The purpose of this study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS), in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00082251
- Testing
- Niacin extended release and simvastatin tablets
- Sponsor
- Kos Pharmaceuticals
Obesity, Dyslipidemia
Regulation of Lipoprotein Metabolism in Obese Men
Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS).
- Conditions
- Obesity, Dyslipidemia, Insulin Resistance
- Trial name
- NCT00392717
- Testing
- Atorvastatin, Fish oils
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The University of Western Australia
Hyperlipidemia, Mixed Hyperlipidemia
Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.
- Conditions
- Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
- Trial name
- NCT00345657
- Testing
- Niacin Extended Release/Lovastatin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- In His Image